TY - JOUR
T1 - Rationale and design of the Kidney Precision Medicine Project
AU - Kidney Precision Medicine Project
AU - de Boer, Ian H.
AU - Alpers, Charles E.
AU - Azeloglu, Evren U.
AU - Balis, Ulysses G.J.
AU - Barasch, Jonathan M.
AU - Barisoni, Laura
AU - Blank, Kristina N.
AU - Bomback, Andrew S.
AU - Brown, Keith
AU - Dagher, Pierre C.
AU - Dighe, Ashveena L.
AU - Eadon, Michael T.
AU - El-Achkar, Tarek M.
AU - Gaut, Joseph P.
AU - Hacohen, Nir
AU - He, Yongqun
AU - Hodgin, Jeffrey B.
AU - Jain, Sanjay
AU - Kellum, John A.
AU - Kiryluk, Krzysztof
AU - Knight, Richard
AU - Laszik, Zoltan G.
AU - Lienczewski, Chrysta
AU - Mariani, Laura H.
AU - McClelland, Robyn L.
AU - Menez, Steven
AU - Moledina, Dennis G.
AU - Mooney, Sean D.
AU - O'Toole, John F.
AU - Palevsky, Paul M.
AU - Parikh, Chirag R.
AU - Poggio, Emilio D.
AU - Rosas, Sylvia E.
AU - Rosengart, Matthew R.
AU - Sarwal, Minnie M.
AU - Schaub, Jennifer A.
AU - Sedor, John R.
AU - Sharma, Kumar
AU - Steck, Becky
AU - Toto, Robert D.
AU - Troyanskaya, Olga G.
AU - Tuttle, Katherine R.
AU - Vazquez, Miguel A.
AU - Waikar, Sushrut S.
AU - Williams, Kayleen
AU - Wilson, Francis Perry
AU - Zhang, Kun
AU - Iyengar, Ravi
AU - Kretzler, Matthias
AU - Himmelfarb, Jonathan
N1 - Publisher Copyright:
© 2021 International Society of Nephrology
PY - 2021/3
Y1 - 2021/3
N2 - Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies. This project is a multicenter prospective cohort study of adults with CKD or AKI who undergo a protocol kidney biopsy for research purposes. This investigation focuses on kidney diseases that are most prevalent and therefore substantially burden the public health, including CKD attributed to diabetes or hypertension and AKI attributed to ischemic and toxic injuries. Reference kidney tissues (for example, living-donor kidney biopsies) will also be evaluated. Traditional and digital pathology will be combined with transcriptomic, proteomic, and metabolomic analysis of the kidney tissue as well as deep clinical phenotyping for supervised and unsupervised subgroup analysis and systems biology analysis. Participants will be followed prospectively for 10 years to ascertain clinical outcomes. Cell types, locations, and functions will be characterized in health and disease in an open, searchable, online kidney tissue atlas. All data from the Kidney Precision Medicine Project will be made readily available for broad use by scientists, clinicians, and patients.
AB - Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies. This project is a multicenter prospective cohort study of adults with CKD or AKI who undergo a protocol kidney biopsy for research purposes. This investigation focuses on kidney diseases that are most prevalent and therefore substantially burden the public health, including CKD attributed to diabetes or hypertension and AKI attributed to ischemic and toxic injuries. Reference kidney tissues (for example, living-donor kidney biopsies) will also be evaluated. Traditional and digital pathology will be combined with transcriptomic, proteomic, and metabolomic analysis of the kidney tissue as well as deep clinical phenotyping for supervised and unsupervised subgroup analysis and systems biology analysis. Participants will be followed prospectively for 10 years to ascertain clinical outcomes. Cell types, locations, and functions will be characterized in health and disease in an open, searchable, online kidney tissue atlas. All data from the Kidney Precision Medicine Project will be made readily available for broad use by scientists, clinicians, and patients.
KW - acute kidney injury
KW - chronic kidney disease
KW - diabetes
KW - hypertension
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85101142744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101142744&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.08.039
DO - 10.1016/j.kint.2020.08.039
M3 - Comment/debate
C2 - 33637194
AN - SCOPUS:85101142744
SN - 0085-2538
VL - 99
SP - 498
EP - 510
JO - Kidney International
JF - Kidney International
IS - 3
ER -